Microglia as Therapeutic Targets in Neurodegenerative Diseases
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
The Scientist’s Creative Services Team | Jul 24, 2023 | 1 min read
Xitiz Chamling shares how advances in human stem cell and gene editing technologies fuel his drive for better multiple sclerosis drug screening platforms.
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
The Scientist Creative Services Team in collaboration with 10x Genomics | Feb 17, 2021 | 1 min read
Paul Thomas from St. Jude Children’s Research Hospital will discuss how he used single cell and spatial transcriptomics to discover the underlying mechanism of an inflammatory immune response in the lungs.
The Scientist’s Creative Services Team | Oct 7, 2020 | 1 min read
Molly Shoichet and Bridget Wagner discuss strategies for using phenotypic screening to identify novel agents against diseases such as cancer and diabetes.
The small molecule is effective in tomato and wheat in laboratory trials, but its scalability and applicability to real-world agriculture remains to be seen.